Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05025722 · ClinicalTrials.gov registry record
Pseudoxanthoma Elasticum (PXE) Natural History Biomarkers in PXE Individuals and Their Biological Non-PXE Siblings
A clinical trial, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- 48
- Enrollment target
NCT05025722 is a clinical trial that has completed, run by Daiichi Sankyo. The registered enrollment target is 48 participants.
The verdict
NCT05025722 has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- 48 participants
- Enrollment target
Study Summary
This PXE biomarker study aims to characterize the levels of inorganic pyrophosphate (PPi), pyridoxal 5´-phosphate (PLP), and other biomarkers relevant to PXE and ectopic calcification in both PXE patients and their biological siblings who are PXE carriers or normal non-PXE individuals.
Interventions
- OTHER Non Interventional
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2021-08-30 |
| Est. Completion | 2022-08-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05025722
The ClinicalTrials.gov registry entry for NCT05025722 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Non Interventional is the first listed.
NCT05025722 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05025722 about?
NCT05025722 is a clinical study titled "Pseudoxanthoma Elasticum (PXE) Natural History Biomarkers in PXE Individuals and Their Biological Non-PXE Siblings". This PXE biomarker study aims to characterize the levels of inorganic pyrophosphate (PPi), pyridoxal 5´-phosphate (PLP), and other biomarkers relevant to PXE and ectopic calcification in both PXE patients and their biological siblings who are PXE carriers or normal non-PXE individuals.
What is the current status of trial NCT05025722?
This trial is currently completed. The enrollment target is 48 participants. The study started on 2021-08-30. Estimated completion is 2022-08-11.
What interventions are being tested in trial NCT05025722?
The interventions under investigation include: Non Interventional (OTHER).
Who is sponsoring clinical trial NCT05025722?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.